120 related articles for article (PubMed ID: 38149340)
1. Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry.
Lim SL; Wellard C; Moore E; Harrison SJ; Hang Q; Ho J; Rajagopal R; Spencer A
Intern Med J; 2024 May; 54(5):773-778. PubMed ID: 38149340
[TBL] [Abstract][Full Text] [Related]
2. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088
[TBL] [Abstract][Full Text] [Related]
4. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Krishnan A; Yong K; Weisel K; Mehra M; Nair S; Qi K; Londhe A; Diels J; Crivera C; Jackson CC; Olyslager Y; Vogel M; Schecter JM; Banerjee A; Valluri S; Usmani SZ; Berdeja JG; Jagannath S
EJHaem; 2022 Feb; 3(1):97-108. PubMed ID: 35846215
[TBL] [Abstract][Full Text] [Related]
6. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Dima D; Abdallah AO; Davis JA; Awada H; Goel U; Rashid A; DeJarnette S; Anwer F; Shune L; Raza S; Mahmoudjafari Z; Williams L; Faiman B; McGuirk JP; Sauter CS; Ahmed N; Khouri J; Hashmi H
Blood Cancer J; 2024 May; 14(1):90. PubMed ID: 38821914
[TBL] [Abstract][Full Text] [Related]
7. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
[TBL] [Abstract][Full Text] [Related]
8. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
9. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
10. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
[TBL] [Abstract][Full Text] [Related]
11. Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).
Bergin K; Wellard C; Augustson B; Cooke R; Blacklock H; Harrison SJ; Ho J; King T; Quach H; Mollee P; Walker P; Moore E; McQuilten Z; Wood E; Spencer A;
Bone Marrow Transplant; 2021 Oct; 56(10):2533-2543. PubMed ID: 34011965
[TBL] [Abstract][Full Text] [Related]
12. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K; Moore E; McQuilten Z; Wood E; Augustson B; Blacklock H; Ho J; Horvath N; King T; McNeil J; Mollee P; Quach H; Reid CM; Rosengarten B; Walker P; Spencer A
BMC Med Res Methodol; 2016 Nov; 16(1):151. PubMed ID: 27829380
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Costa LJ; Hari P; Berdeja JG; De Stefano V; Gay F; Hooper B; Bartlett M; Haltner A; Rosta E; Kumar S; Martin T; Mateos MV; Moreau P; Usmani SZ; Olyslager Y; Schecter JM; Roccia T; Garrett A; Lee S; Nesheiwat T; Pacaud L; Zhou C; Samjoo IA; Lin Y; Diels J; Valluri S; Weisel K
Curr Med Res Opin; 2022 Oct; 38(10):1759-1767. PubMed ID: 35815818
[No Abstract] [Full Text] [Related]
14. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
15. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.
Mateos MV; Weisel K; Diels J; Arribas A; Tamayo M; Schecter JM; Roccia T; Haddad I; Pacaud L; Moreau P
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):224-231.e2. PubMed ID: 38212206
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
[TBL] [Abstract][Full Text] [Related]
17. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
18. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
[TBL] [Abstract][Full Text] [Related]
19. Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Minarik J; Radocha J; Jungova A; Straub J; Jelinek T; Pika T; Pour L; Pavlicek P; Harvanova L; Pospisilova L; Krhovska P; Novakova D; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Maisnar V; Hajek R
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291949
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S
Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
